💊Takeda notes statement by Shire plc regarding revised proposal and extension of PUSU deadline to May 8, 2018
Category: Pharmaceutical
💊Otsuka’s JYNARQUE™ Approved by U.S. FDA as the First Treatment to Slow Kidney Function Decline in Adults at Risk of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)
💊Takeda Statement Regarding Improved Proposal for Shire plc
💊Takeda Statement Regarding Shire plc
💊FDA & DRUG TODAY